Plenary Session: Biliary  by unknown
© 2012 The Authors
HPB 2012, 14 (Suppl. 2), 1–12 HPB © 2012 Americas Hepato-Pancreato-Biliary Association
PLENARY SESSION: BILIARY
PL01
A 21-YEAR ANALYSIS OF T1 
GALLBLADDER CARCINOMA: 
IS CHOLECYSTECTOMY 
ALONE ADEQUATE?
D. Hari1, J. H. Howard1, A. Leung1, C. Chiu1, M.-S. Sim1 
and A. Bilchik1,2
1John Wayne Cancer Institute, Santa Monica, CA, USA; 
2California Oncology Research Institute, Santa Monica, 
CA, USA
Introduction: Gallbladder carcinoma (GBCA) is a rare 
disease that is often diagnosed incidentally in early stages. 
Simple cholecystectomy is considered the standard treatment 
for T1 GBCA. We hypothesized that the extent of surgery 
might affect survival in a large cohort of patients with T1 
GBCA.
Methods: The Surveillance, Epidemiology, and End Results 
(SEER) Database was queried to identify patients whose 
microscopically confi rmed, localized GBCA (Stage I) was 
diagnosed between 1988 and 2008. Surgical treatment was 
categorized as cholecystectomy alone (CS), cholecystectomy 
with lymph node dissection (CS + LN) or radical cholecys-
tectomy (RCS). Age, gender, race, ethnicity, T1 sub-stage 
(T1a, T1b or T1NOS), radiation treatment, extent of surgery, 
cause of death, and survival were assessed by Logrank and 
Cox regression analysis.
Results: Of 2788 patients with localized GBCA, 1159 had 
pathologically confi rmed T1a (confi ned to mucosa, lamina 
propria, or submucosa), T1b (confi ned to muscularis 
propria) or T1NOS (less than T2 but not specifi ed) cancer. 
At a median follow-up of 22 months, 336 patients (29%) 
died of GBCA. The 5-year survival associated with CS, CS 
+ LN, and RCS was 50%, 70% and 79% respectively (p < 
0.0001). On regression analysis, surgical treatment and 
younger age were predictive of improved survival (p < 
0.0001) while radiation therapy portends worse survival 
(p = 0.0002).
Conclusion: In the largest series of T1 GBCA reported, 
survival was signifi cantly impacted by the extent of surgery 
(LN dissection and RCS) in T1 GBCA. Cholecystectomy 
alone is inadequate for T1 GBCA and should not be consid-
ered standard treatment.
PL02
LAPAROSCOPIC CHOLECYSTECTOMY 
IS MORE DIFFICULT AFTER 
PREVIOUS ERCP
J. S. Reinders1, J. Heisterkamp2, D. J. Gouma3 and 
D. Boerma1
1Department of Surgery, St. Antonius Hospital, Nieuwegein, 
The Netherlands; 2Department of Surgery, St. Elisabeth 
Hospital, Tilburg, The Netherland; 3Department of Surgery, 
Academic Medical Center, Amsterdam, The Netherlands
Introduction: Endoscopic retrograde cholangiography 
(ERCP) with endoscopic sphincterotomy (ES) is accepted 
in most countries as treatment of choice for patients with 
choledocholithiasis. In case of residual gallbladder stones 
generally a laparoscopic cholecystectomy (LC) is performed. 
Conversion rate for LC after a previous ES has been described 
to range from 8–55% compared to less than 5% in uncom-
plicated cholelithiasis.
Methods: The aim of the present study was to assess the 
complexity of LC after ES for choledocholithiasis compared 
with LC for uncomplicated cholelithiasis. The study groups 
consisted of two patient cohorts; patients who had undergone 
a previous ERCP with ES for choledocholithiasis and patients 
with cholecystolithiasis who had no previous intervention 
prior to LC. Ninety-three patients who had undergone ES 
prior to LC (PES) were derived from a multicenter rand-
omized clinical trial analyzing the effects of the timing of 
LC after ES. Operative details and the clinical course of these 
patients were compared to a prospective consecutive cohort 
of 83 patients who underwent electively planned, laparo-
scopic cholecystectomies, without previous ERCP (NPES).
Results: Baseline characteristics were the same in both 
groups. The median length of LC was 60 mins (IQR 45–71.5) 
in the PES group vs 43 mins (IQR 30–60) for NPES group 
(p < 0.001). Median diffi culty of the LC was 5 for the PES 
group (on a 0–10 scale) versus 3 for the NPES group (p = 
0.002). There were 6 conversions in the PES group (6.5%) 
compared to 2 in the NPES group (2.4%, p = 0.200). 
Complications occurred in 12 patients from the PES group 
(12.9%) and in 8 patients in NPES group (9.6%) (p = 0.497). 
Notably cystic stump leakage occurred more often in patients 
who had undergone previous ES (n = 4 (4.3%) versus 1 
patient (1.2%, p = NS). The difference in complexity en 
length of LC was persistent after statistical correction for 
experience of the surgical team.
Conclusion: Laparoscopic cholecystectomy after ES is 
lengthier and more diffi cult than in uncomplicated cholelithi-
asis and should therefore perhaps be performed by an expe-
rienced surgeon. The higher incidence of cystic duct leakage 
may require closing the cystic duct with a loop rather than a 
clip.
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A PHASE III RANDOMIZED, 
CONTROLLED, SUPERIORITY STUDY 
EVALUATING THE FIBRIN PAD VERSUS 
STANDARD OF CARE TREATMENT IN 
CONTROLLING PARENCHYMAL 
BLEEDING DURING ELECTIVE 
HEPATIC SURGERY
J. Koea1, J. Batiller2, B. Patel2, J. Shen2, J. Hammond2, 
J. Hart2, C. Fischer3 and J. Garden4
1Auckland City Hospital, Grafton, Auckland, New Zealand; 
2Ethion Inc, Somerville, NJ, USA; 3The Methodist Hospital 
and Weil Medical College of Cornell University, Houston, 
TX, USA; 4Royal Infi rmary of Edinburgh, Edinburgh, UK
Introduction: Hemostasis following liver resection may be 
diffi cult to achieve due to the presence of challenging bleed-
ing, the anatomic landscape of the liver, and the quality of 
tissue making up the hepatic parenchyma. The fi brin pad 
(FP) is a topical absorbable hemostat designed to be effective 
in a variety of tissues and across multiple bleeding intensi-
ties. This is the fi rst clinical trial evaluating the hemostat’s 
safety and effectiveness in controlling bleeding during elec-
tive hepatic resection.
Methods: This prospective, randomized trial enrolled 104 
subjects in 5 countries. Following parenchymal transection, 
subjects with an appropriately defi ned target bleeding site 
(TBS) were stratifi ed according to the type of hepatic 
parenchyma, and immediately randomized 1 : 1, FP versus 
Standard of Care (SoC). SoC included manual compression 
± the use of an approved topical absorbable hemostat. The 
main endpoint was hemostasis at 4 minutes from identifi ca-
tion of the TBS, with no re-bleeding requiring re-treatment 
prior to abdominal closure. Results were stratifi ed for 
both normal and abnormal (steatosis or cirrhosis) hepatic 
parenchyma. All subjects were followed for 60 days 
post-operatively.
Results: The intent to treat analysis showed an overall treat-
ment difference of 53.0% (p < 0.0001), 82.5% (33/40 FP) 
vs. 29.5% (13/44 SoC) in achieving hemostasis at 4 minutes. 
The per protocol analysis showed an overall treatment dif-
ference of 65.7% (p < 0.0001), with 33/35 successes (94.3%) 
in the FP group and 12/42 in the SoC group (28.6%). The 
stratifi cation results showed treatment differences between 
the normal parenchyma group, 63.6% (95.8% FP vs. 32.3% 
SoC p < 0.0001) and a larger difference of 72.7% in the 
abnormal parenchyma group (90.9% FP vs. 18.2% SoC 
p = 0.0003). Postoperative intra-abdominal fl uid collections 
were less frequent in the FP group (3.4% FP versus 13.3% 
SoC p = 0.059). There was no difference in safety profi le 
between FP or SoC groups.
Conclusion: FP is safe and effective when used as an 
adjunct to hemostasis during hepatic surgery. The success 
rate of achieving hemostasis with FP remained high com-
pared to the standard of care group, especially in steatotic or 
cirrhotic liver tissue where the control success rates dimin-
ish. In addition, FP treatment of hepatic parenchymal sur-
faces may reduce the risk of post-operative biliary and fl uid 
collections.
PL04
PRECISION NEOADJUVANT 
TRANSARTERIAL 
CHEMOEMBOLISATION USING 
IRINOTECAN ELUTING BEADS (DEBIRI-
TACE); UPDATE ON A PHASE 2 STUDY
R. Jones1, D. Dunne1, P. Sutton1, E. O’Grady2, 
M. Terlizzo3, S. Fenwick4, H. Malik4 and G. Poston4
1Institute of Translational Medicine, University of 
Liverpool, Liverpool, Merseyside, UK; 2Department of 
Radiology, Aintree University Hospital NHS Foundation 
Trust, Liverpool, UK; 3Department of Histopathology, 
Aintree University Hospital NHS Foundation Trust, 
Liverpool, UK; 4Department of Hepatobiliary Surgery, 
Aintree University Hospital NHS Foundation Trust, 
Liverpool, UK
Introduction: Chemotherapy can increase the number of 
patients with CRLM bought to resection and degree of patho-
logical response to chemotherapy correlates well with overall 
survival. Irinotecan eluting beads are delivered to tumour 
intra-arterially, where they provide controlled & sustained 
delivery of Irinotecan directly to tumour, maximising 
response and reducing systemic exposure. This study aimed 
to examine the feasibility and safety of a single neoadjuvant 
bead embolisation 1 month before hepatectomy.
Methods: Patients with easily resectable colorectal liver 
metastases received DEBIRI-TACE 1 month before surgery. 
Primary end-point was tumour resectability. Secondary end 
points included pathological tumour response and safety.
Results: TACE attempted in 49 patients and was successful 
in 40. Reasons for failed TACE included arterial abnormality 
(n = 2), progressive disease (n = 2), bilobar disease (n = 2), 
hepatoma (n = 1), allergy to contrast (n = 1) and concomitant 
infection (n = 1). There was 1 post-TACE liver abscess (3%), 
and 1 post TACE pancreatitis (3%) (recognised complica-
tions). 38 patients have undergone hepatic resection so far, 
with R0 resection rate of 100% and no signifi cant post-
hepatectomy morbidity. Thirty day post-operative mortality 
was 7.6% (n = 2), with neither death related to TACE. 
Complete pathological response (no viable tumour) was 
demonstrated in 16% of lesions, major response in 61% and 
minor response in 23%.
Conclusion: Neoadjuvant DEBIRI TACE for resectable 
colorectal liver metastasis is safe and is not associated with 
increased post-hepatectomy morbidity. A single treatment 
with DEBIRI-TACE resulted in pathological response of 
tumour similar to that seen after systemic treatment, which 
may translate to improved progression free survival.
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LAPAROSCOPIC LIVER RESECTION 
FOR HEPATOCELLULAR CARCINOMA: 
A FRENCH MULTICENTRIC STUDY 
INCLUDING 351 PATIENTS
C. Goumard1, A. Laurent2, H. Tranchart3, S. Truant4, 
B. Gayet5, C. Salloum6, G. Luc7, S. Dokmak8, T. Piardi9, 
D. Cherqui2, I. Dagher10, E. Boleslawski4, E. Vibert6, 
A. Sa Cunha6, J. Belghiti8, P. Pessaux9, O. Scatton1, 
O. Soubrane1
1Saint Antoine Hospital, Paris, France; 2Henri Mondor 
Hospital, Créteil, France; 3Antoine Béclère 
Hospital,Clamart, France; 4Lille University Hospital, Lille, 
France; 5Institut Mutualiste Montsouris, Paris, France; 
6PaulBrousse Hospital, Villejuif, France; 7Pellegrin 
University Hospital, Bordeaux, France; 8Beaujon Hospital, 
Clichy, France; 9Nouvel Hopital Civil, Strasbourg, France; 
10Department of Minimally Invasive Abdominal Surgery 
- 157 rue de la Porte de Trivaux, Clamart, France
Introduction: In selected patients, laparoscopic resection 
of hepatocellular carcinoma (HCC) seems to provide good 
oncologic outcomes, comparable to those of open surgery. 
However, current studies report the results obtained in short 
cohorts. Since France was a country involved very early in 
the development of laparoscopic surgery, we decided to 
report the results of a multicentric experience in HCC resec-
tion in order to analyse the oncologic outcomes at a nation-
wide level.
Methods: A total of 351 patients underwent laparoscopic 
liver resection for HCC from 1996 to 2011 in 9 French 
centers experienced in laparoscopic liver surgery. Patient’s 
characteristics, postoperative mortality and morbidity, and 
long term survival were retrospectively reviewed and 
analysed.
Results: 85% of the patients had underlying liver disease. 
Types of resection were the following: wedge resections 
41%, left lateral sectionectomy 27%, segmentectomy 24%, 
and major hepatectomy 11%. Median operative time was 
180 min. Conversion to laparotomy occurred in 13% and 
blood transfusion was necessary in 8% of cases. Overall 
morbidity rate was 22% and postoperative mortality rate 2% 
(6 patients). Bile leak occurred in 2% of cases. Median hos-
pital stay was 7 days. Surgical margins were R0 in 92% of 
cases (median margin: 10 mm). Overall and recurrence-free 
survival rates at 1, 3 and 5 years were 90.3%, 70.1%, 63.9%, 
and 85.2%, 55.9%, 40.4% respectively, with a median follow 
up of 19.5 months.
Conclusion: This multicentric study confi rms in a large 
cohort that laparoscopic liver resection for HCC is not only 
a safe procedure but also an effi cient approach to HCC treat-
ment. Considering the good oncologic results and low mor-
bidity rates obtained in 351 patients, this study adds new 
robust data to consider the laparoscopic approach as a fi rst-
line treatment for resectable HCC.
PL06
EVALUATION OF THE 7TH AJCC/TNM 
STAGING FOR PATIENTS WITH 
CURATIVE RESECTION FOR 
HEPATOCELLULAR CARCINOMA
A. Chan, S. T. Fan, R. Poon, S. C. Chan, K. Chok, 
T. T. Cheung and C. M. Lo
Division of Hepatobiliary and Pancreatic Surgery, Liver 
Transplantation, Department of Surgery, Queen Mary 
Hospital, The University of Hong Kong, Hong Kong
Introduction: The American Joint Committee on Cancer 
(AJCC) tumor-node-metastasis (TNM) staging and the 
Japanese TNM (jTNM) staging systems are widely accepted 
by surgeons for prognostication of patients with curative 
resection for hepatocellular carcinoma (HCC). This study 
aims to evaluate the prognostic predictability of the latest 7th 
edition AJCC/TNM staging (7th TNM) and compared its 
accuracy with the 5th and 6th AJCC/TNM staging, and the 
jTNM staging.
Methods: The clinicopathological data of 754 patients who 
received curative hepatectomy for HCC between 1989 and 
2005 were reviewed. All patients were followed up at least 
60 months. Tumor-free survival formed the primary end-
point for survival analysis and was estimated by Kaplan 
Meier method. Survival difference between subgroups was 
compared by log-rank test. Independent prognostic factors 
for tumor-free survivals were identifi ed by multivariable 
analysis. The accuracy of the 7th TNM was compared with 
the other staging systems by a Cox-regression model.
Results: According to the 7th TNM system, the 1-, 3- and 
5-year survival for stage I tumor was 81.6%, 60.3% and 
50.6%; for stage II tumor was 50.7%, 27.9%, and 21.0%; for 
stage IIIA tumor was 31.5%, 19.1% and 14.6%; for stage 
IIIB tumor was 21.2%, 15.2% and 12.1%; and for stage IIIC 
tumor was 36.6%, 17.2% and 12.9%. There was signifi cant 
survival difference in stage I vs II (P < 0.001), stage II vs 
IIIA (P = 0.02) but the differences in stage IIIA vs IIIB (P = 
0.07), and IIIB vs IIIC (P = 0.23) were not signifi cant. The 
independent prognostic factors were microvascular invasion, 
tumor multiplicity, bilobar disease and tumor size ≥5 cm. 
The 5th TNM was found to be the most accurate in prognos-
tic prediction followed by the 6th TNM, the 7th TNM, and 
jTNM.
Conclusion: The 7th AJCC/TNM staging system could 
adequately stratify patients with early HCC. However, stage 
IIIC tumor appeared to have better survival than stage IIIB 
tumor. Further studies are needed to evaluate the prognostic 
implications of tumor characteristics in advanced HCC. 
Inclusion of microvascular invasion and lobar distribution 
might enhance the staging accuracy and re-classifi cation of 
stage IIIB and IIIC may be more appropriate in future TNM 
staging.
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COAGULOPATHY FOLLOWING LIVER 
RESECTION: IS IT OVERDIAGNOSED 
AND OVERTREATED?
J. Barton, G. Riha, J. Differding, R. Pommier, S. Orloff, 
B. Sheppard, M. Schreiber and K. Billingsley
Oregon Health and Science University, Portland, OR, USA
Introduction: International Normalized Ratio (INR) is 
widely utilized in determining plasma replacement and use 
of thromboprophylaxis after liver resection. The link between 
INR and functional coagulopathy remains poorly under-
stood. Thrombelastography (TEG) monitors shear elasticity, 
which is sensitive to cellular and plasma components of 
blood, allowing for functional assessment of the natural 
history of a clot. The aim of this study was to prospectively 
compare INR and TEG in liver resection patients.
Methods: Forty patients were enrolled prior to undergoing 
elective hepatectomy. Patients underwent liver resection 
utilizing low CVP anesthetic technique and intermittent 
Pringle maneuver. INR and TEG were drawn prior to inci-
sion, post-operatively, and post-operative days 1, 3, and 5.
Results: INR values increased signifi cantly at all time 
points when compared to pre-operative INR (p < 0.01). The 
time to onset of clot (R-value) decreased signifi cantly at the 
post-operative time point (p = 0.04) consistent with relative 
hypercoagulability. Subsequent R-values were not statisti-
cally different when compared to the pre-operative R-value. 
The strength of the clot (maximum amplitude (MA)) was 
unchanged when comparing pre- and post-operative time 
points.
Conclusion: Despite an elevation in INR, patients who 
underwent liver resection did not demonstrate a hypocoagu-
lopathic state, but demonstrated a brief hypercoagulable state 
based on TEG. There was no evidence of weakening of the 
clot based on TEG. These data call into question the practice 
of utilizing the INR to guide plasma transfusion and timing 
of prophylactic anticoagulation after liver resection.
PL08
LIVER RESECTION FOR 
HEPATOCELLULAR CARCINOMA IN 
CIRRHOTIC PATIENTS WITH AN 
ELEVATED SERUM ALANINE 
AMINOTRANSFERASE
C.-C. Wu, S.-B. Cheng, C.-C. Yu and J. Wang
Taichung Veteans General Hospital, Taichung, Taiwan 
Introduction: Liver resection remains a curatively thera-
peutic option for hepatocellular carcinoma (HCC) even in 
cirrhotic patents. On the other hand, elevated serum ami-
notransferase has been regarded as liver cell injury or liver 
dysfunction. Liver resection was claimed as high risky in 
cirrhotic patients with a high serum aminotransferase in last 
century. However, long-term results of such cirrhotic patients 
remain unclear.
Methods: A retrospective review of a prospectively col-
lected data was performed on 978 cirrhotic patients who 
underwent a curative liver resection between 2000 and June 
2011. Among them, the preoperative serum alanine ami-
notransferase (ALT) level > 100 U/l (normal 10–50 U/l) was 
found on 218 patients (range 1060–835 U/l). Liver resection 
strategies were based on indocyanine clearance rate and 
tumor extension. The clinicopathological characteristics, 
early and long-term results after hepatectomy of these 218 
patients (group A) are compared with those of the other 760 
cirrhotic patients whose serum ALT was ≤100 U/l (group B).
Results: The group A patients had a signifi cant greater indo-
cyanine 15-min retension rate, higher rate of associated with 
hepatitis B or C infection and higher Ishak fi brotic score. The 
operative time in group A (4.56 + 1.95 h) was signifi cantly 
higher than group B (4.33 + 1.45 h, p = 0.023). Although 
higher postoperative complication occurred in 65 (29.8%) of 
group A and 137 (18.0%) of group B (p < 0.0001), operative 
deaths ensued in 4 (0.53%) group B patients and 0 group A 
patients (p = 0.581). The 5-year disease-free survival rates in 
group A and B were 55.2% and 51.5% respectively (p = 
0.522) while overall 5-year survival rates in group A and B 
were 57.5% and 60.9% respectively (p = 0.485).
Conclusion: After improving perioperative assessments in 
21 century, although cirrhotic patients with high serum ALT 
had higher postoperative morbidity, no differences could be 
found in postoperative mortality with a comparable long-
term results. Thus, liver resection for HCC remains justifi ed 
in selected cirrhotic patients with an elevated serum ALT.
PL09
SAFETY OF LAPAROSCOPIC LIVER 
RESECTION IN THE SETTING 
OF CIRRHOSIS
R. Cannon1, M. Killackey2 and J. Buell2
1Department of Surgery, University of Louisville, 
Louisville, KY, USA; 2Department of Surgery,Tulane 
Abdominal Transplant Institute, New Orleans, LA, USA
Introduction: In the last decade, laparoscopic liver resec-
tion has gained ground as an attractive alternative to an open 
procedure, particularly in patients with normal liver paren-
chyma and benign indications. Cirrhotics represent a more 
fragile and challenging group that are often avoided in early 
experiences with minimally invasive hepatectomy. This 
study was undertaken to evaluate the feasibility of laparo-
scopic liver resection in cirrhotic patients.
Methods: With IRB approval, a retrospective review of all 
patients undergoing laparoscopic hepatectomy by a single 
group of surgeons was undertaken, with analysis focused on 
patients with cirrhosis. Where appropriate, comparisons 
were made with noncirrhotic patients undergoing laparo-
scopic hepatectomy by the same group. Patient and tumor 
characteristics, as well as perioperative and in hospital 
outcomes were analyzed. Continuous variables were ana-
lyzed with Student’s t-test, while categorical covariates were 
examined using chi-squared. Univariate and multivariate 
logistic regression were performed to determine factors asso-
ciated with complications and 90 day death in the cirrhotic 
cohort.
Results: There were a total of 327 patients in this series, 52 
of whom were cirrhotic. The majority of cirrhotic patients 
were Child’s class A (90.4%). Non-cirrhotic patients had 
signifi cantly larger tumors with more segments resected. 
Blood loss was 260 ml vs. 215 ml (p = 0.375) in the cirrhotic 
vs. noncirrhotic group, while operative time was 2.3 vs. 2.6 
hours (p = 0.051). Morbidity in the cirrhotic vs. noncirrhotic 
group was 25.0% vs. 17.5% (p = 0.200), while the 90 day 
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death rate was 5.8% vs. 1.1% (p = 0.054). LOS was 4.0 vs. 
3.4 days (p = 0.210). Only age (OR 1.188; p = 0.017) was 
signifi cantly associated with complications in cirrhotic 
patients on multivariate analysis. Only blood loss (OR 1.003; 
p = 0.021) was signifi cantly associated with 90 day death.
Conclusion: Laparoscopic liver resection in cirrhotic 
patients appears best suited to those with compensated liver 
function and small tumors amenable to limited resection. 
When such selection criteria are applied, the procedure is 
safe and effective in experienced hands.
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HEPATITIS C INFECTION AND 
HEPATOCELLULAR CARCINOMA 
IN LIVER TRANSPLANT: 
A TWENTY-YEAR EXPERIENCE
S. Dumitra, S. AlAbad, M. Hassanain, M. Cantrovitch, 
J. Barkun, P. Metrakos, P. Chaudhury and J. Tachervenkov
Hepatobilliary Surgery, Mcgill University Health Center, 
Montreal, Canada
Introduction: Hepatitis C infection (HCV) and hepatocel-
lular carcinoma (HCC) are two of the main causes of liver 
transplantation. HCV and HCC have been shown to reduce 
survival after orthotropic liver transplantation (OTL). We 
wanted to assess if HCV and HCC impact survival after OTL 
more when they occur together when compared to HCC or 
HCV alone.
Methods: Patients who underwent OTL (n = 601) at our 
institution from 1992 to 2011 were reviewed. Patients 
deceased within 30 days (n = 69) and retransplants (n = 49) 
were excluded. Recipients were divided into 4 groups: those 
transplanted for other causes (n = 252) (control group), those 
with HCC alone (n = 58), those with HCV (n = 106) and 
those with both HCV and HCC (n = 67). Demographics, 
donor risk index (DRI), Model for End-stage Liver Disease 
(MELD) score, survival, complications within 90 days and 
tumor characteristics when available (n = 113) were col-
lected. Statistical analysis was done using ANOVA for 
demographics, COX or Kaplan Mayer for survival, logistic 
regression for recurrence and Chi-square or Fisher’s exact 
tests for univariate analysis.
Results: Groups were comparable for MELD, DRI, compli-
cations, length of ICU stay, but HCC patients were older. 
After adjusting for age, MELD, sex, and DRI, survival was 
lower in the HCC+/HCV+ group (59% at 5 yrs), the hazard 
ratio (HR) being 1.90 (95% CI, 1.23–2.94, p < 0.004) and 
1.45 (CI, 0.98–2.11, p = 0.057) for HCC−/HCV+. The HCC 
survival was comparable to controls (1.16 (0.70–1.93), p = 
0.55). HCV and HCC recurrence rates and recurrence-free 
survival were similar amongst groups. Tumor characteristics 
and pre-OTL treatment were the similar except for Milan 
criteria (50% vs 31%, p < 0.04) and micro-vascular invasion 
(40% vs 22%, p < 0.04). HCC+/HCV+ vs HCC+/HCV− sur-
vival remained lower (1.99, CI 1.02–3.87, p < 0.04) after 
correcting for tumor characteristics and treatment.
Conclusion: Patients with HCV have a signifi cantly lower 
survival after liver transplantation when compared to HCV 
negative patients, whereas HCC alone has almost no 
impact on patient survival in our group. Patient survival 
is dramatically decreased when HCC and HVC are both 
present but the attributable impact of HCV is greater than 
that of HCC.
PL11
NEOADJUVANT CHEMORADIOTHERAPY 
FOLLOWED BY LIVER 
TRANSPLANTATION FOR 
UNRESECTABLE 
CHOLANGIOCARCINOMA: A SINGLE 
CENTRE NATIONAL EXPERIENCE
S. Duignan, D. Maguire, S. Ravichand, J. Geoghegan, 
E. Hoti and O. Traynor
Liver Unit, St Vincents University Hospital, Dublin, Ireland
Introduction: In 2004, the Mayo Clinic reported 82% 5 
year survival for patients with localised unresectable hilar 
cholangiocarcinoma (CCA) treated by neoadjuvant chemo-
radiotherapy (CRT) followed by liver transplantation (OLT).
This approach has not yet been widely accepted. This study 
was undertaken to determine if the Mayo Clinic results could 
be replicated in a single centre national OLT centre.
Methods: Twenty seven patients with unresectable hilar 
CCA (9 pts) or CCA/primary sclerosing cholangitis (18 pts) 
were considered for the Mayo Clinic protocol over 6 years. 
Hilar CCA patients were deemed unresectable based on 1) 
imaging features; 2) review by at least 2 experienced HPB 
surgeons. Preliminary workup was designed to 1) establish 
a tissue diagnosis; 2) exclude locoregional or systemic 
spread. Neoadjuvant therapy consisted of internal brachy-
therapy plus external beam radiotherapy, combined with 
initial 5 FU chemotherapy and maintenance capecitabine. At 
completion of neoadjuvant treatment, all patients had either 
laparoscopy or mini laparotomy.
Results: Seven patients were excluded because of disease 
progression prior to OLT. Twenty patients had OLT (7 com-
bined with Whipples procedure). Three patients required 
urgent re-transplantation (vascular thrombosis).Four patients 
died in hospital (20% hospital mortality).Of 16 patients who 
left hospital, 1 patient developed early recurrence at 5 months 
and died at 6 months. Five other patients developed recur-
rence at 10, 15, 26, 34 and 39 months. Ten patients (50%) 
are currently alive and disease free at a median 39 months 
after treatment. Actual 1 year survival is 75% and actuarial 
(Kaplan Meier) 3 year survival is 61%.
Conclusion: We have not been able to replicate the excel-
lent Mayo Clinic results. However, we have shown that care-
fully selected patients with unresectable CCA can achieve 
reasonable survival prospects by neoadjuvant CRT followed 
by OLT. The perioperative mortality in these patients is 
higher and the long-term survival is lower than for other OLT 
indications.
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DOWNSTAGING AND RADICAL 
RESECTION AFTER RADIOFREQUENCY 
ABLATION OF LOCALLY ADVANCED 
PANCREATIC CARCINOMA
A. Giardino1, I. Frigerio1, R. Girelli1, P. Regi1, S. Gobbo2, 
M. Bacchion3, R. Salvia3 and C. Bassi3
1Hepatopancreatobiliary Unit, Pederzoli Clinic, via Monte 
Baldo, 37019 Peschiera del Garda (VR), Italy; 2Pathology 
Department, Pederzoli Clinic, via Monte Baldo, 37019 
Peschiera del Garda (VR), Italy; 3Surgical and 
Oncological Department, University of Verona, Piazzale 
Scuro, 37134 Verona (VR), Italy
Introduction: Pancreatic carcinoma still remains an aggres-
sive entity with poor prognosis. Only 20% of pts are resect-
able at diagnosis. Downstaging rate is 8%. Survival of locally 
advanced pancreatic cancers (LAPC) is poor. Radiofrequency 
Ablation (RFA) increases tumour temperature causing cel-
lular death. Our previous study on feasibility and safety of 
RFA in LAPC opened new approaches. Aim is to determine 
the downstaging rate and describe new pathological patterns 
found on the specimens resected after RFA.
Methods: We collected all the patients with histologically 
proven adenocarcinoma enrolled for the phase II pilot study, 
consecutively treated with surgical US-guided RFA.
Three-monthly follow-up was planned with clinical evalu-
ation, CT scan and serum markers (Ca 19–9. Only patients 
with follow-up at least of 6 months were considered for the 
study.
Results: 147 pts were consecutively treated with RFA from 
Feb 2007 to May 2011. Median progression free survival 
(PFS) was 11 mts (IQR 6–15). Downstaging was achieved 
in 13 pts (8.8%) with an overall survival (OS) of 30 mts 
(IQR 26.5–36.25). 6 pts resected, 7 judged technically unre-
sectable and subjected to a 2nd RFA. Median PFS of resected 
was 24 mts (IQR 18–25) and OS 28 mts (IQR 17.5–38.5). 
2 pts dead of disease at 28 mts, one alive with progression, 
3 disease free after 42, 14 and 12 mts. Median PFS of the 
double RFA was 22 mts (IQR 19.25–25.5) and OS 33 mts 
(IQR 28.5–36.5). One alive with stable disease. Path analysis 
showed complete regression in 2 cases, 3 huge fi brosis with 
isolated carcinoma cells (T1N0M0) and 2 invasive carci-
noma (T2N1).
Conclusion: Although RFA seems to prolong survival of 
unresectable stages it doesn’t increase so far the downstaging 
rate if compared to standard therapy. The cases described 
represent the fi rst specimens in the world of a pancreatic 
cancer treated with RFA. The strong fi brotic reaction with 
2 cases of complete regression and three cases of cancer 
cells micro aggregate represent an entirely new pathological 
feature.
PL13
COMPARISON OF PATHOLOGICAL 
RADICALITY BETWEEN OPEN 
AND LAPAROSCOPIC 
PANCREATICODUODENECTOMY 
IN A TERTIARY CENTRE
C. Palanivelu, P. Senthilnathan, A. G. Alwar Ramanujan, 
P. S. Rajan, S. Rajapandian and P. Praveenraj
GEM Hospital & Research Centre, Coimbatore, India
Introduction: Laparoscopic pancreaticoduodenectomy for 
management of periampullary and pancreatic tumors is 
emerging and is still not been accepted as the standard of 
care. The main controversy with this procedure is the extent 
of oncological radicality that can be obtained especially 
along the superior mesenteric vessels and peripancreatic 
region. This paper evaluates the pathological radicality of 
laparoscopic pancreaticoduodenectomy in comparison to 
open procedure at our institute.
Methods: All patients who underwent PD for periampullary 
malignancies at our hospital from March 2006 to February 
2011 were enrolled in the study. For patients operated before 
March 2009 the details were collected retrospectively. 
Clinical reports, pathological slides and specimens and 
reports from a prospectively collected database were ana-
lysed and the details are entered in a standard protocol 
format. All patients who underwent laparoscopic pancreatico 
duodenectomy (LPD) and open pancreaticoduodenectomy 
(OPD) for malignant lesions of periampullary and pancreatic 
head with curative indent were included in this study. The 
study group includes both classical Whipple’s (CPD) and 
Pylorus preserving Pancreaticoduodenectomy (PPD).
Results: 185 patients underwent PD between March 2006 
and February 2011. Patients with benign diseases and vascu-
lar resection were excluded from the study. Of the remaining, 
45 underwent Lap PD and 118 underwent open PD. The 
mean age in Lap PD was 54 and Open PD was 56 years. The 
average tumour size is less in LPD group than OPD group 
(2.8 vs. 3.1 cm respectively, P value of 0.066). The differ-
ence in the average number of lymph nodes removed by 
either method was not statistically signifi cant (18 vs. 17) and 
margin positivity rate was also similar. There was no differ-
ence in R1 status between the study groups even when 
individual margins were compared separately. The average 
length of various margins was also comparable between the 
two groups.
Conclusion: The pathological analysis of radicality between 
laparoscopic and open pancreatico duodenectomy shows 
equal results in terms of lymph node yield, margin positivity 
and clearance. Survival based randomized studies are needed 
to ascertain whether these results are transformed into equal 
survival rates on a long term basis.
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PL14
PANCREATICODUODENECTOMY 
(PD) FOR DUCTAL PANCREATIC 
ADENOCARCINOMA (PA): RESULTS OF 
A FRENCH TERTIARY REFERRAL 
CENTERS PROSPECTIVE 
MULTICENTRIC EVALUATION OF THE 
MARGINS OF RESECTION IN 138 
EVALUABLE PD SPECIMENS
J.-R. Delpero1, P. Bachellier2, N. Regenet3, P. Le Treut4, 
F. Paye5, N. Carrere6, A. Autret7 and G. Ranchin-Monges8
1Department of Surgery, Institut Paoli Calmettes, 
Marseille, France; 2Department of Surgery, Hopitaux de 
Strasbourg, Strasbourg, France; 3Department of Surgery, 
Centre Hospitalo Universitaire de Nantes, Nantes, France; 
4Department of Surgery, Assistance Publique Hopitaux de 
Marseille; Marseille, France; 5Department of Surgery, 
Assistance Publique Hopitaux de Paris, Paris, France; 
6Department of Surgery, Centre Hospitalo Universitaire de 
Toulouse, Toulouse, France; 7Department of Biostatistics, 
Institut Paoli Calmettes, Marseille, France; 8Department of 
Histopathology, Institut Paoli Calmettes, Marseille, France
Introduction: The currently reported R1 resection rates 
after PD for ductal pancreatic adenocarcinoma range between 
5% and 85% in the published literature. Recent publications 
have demonstrated the impact of the systematic use of a 
standardized protocol for histopathologic evaluation (SPHE) 
on margin status in pancreatic cancer. Underreporting of 
microscopic margin involvement is frequent and cause dis-
crepancy between margin status and clinical outcome. Efforts 
to move this fi eld forward are needed.
Methods: A prospective multicentric study was conducted 
(2007–2009); 214 patients with periampullary tumors signed 
the inform consent before laparotomy and 138 macroscopi-
cally margin-free true ductal adenocarcinomas entered the 
present study. The PD was standardized with a «quality 
protocol»; 34 patients (24.6%) had venous resection (VR). 
Multicolour inking by the surgeon clearly identifi es the 
margins: mesenterico-portal vein groove (PV-SMVm; medial 
circumferential margin), superior mesenteric artery (SMAm) 
and posterior margin (Pm). Margins were stratifi ed by 0.5 mm 
increments (0 to 2 mm). Pancreatic neck, bile duct and diges-
tive margins were also analyzed. A logistic regression was 
used to examine the corelation between pathologic factors.
Results: Microscopic involvement was present on at least 
one of the inked margins in 29% of the specimen for 0 mm 
margin, 66% and 68% for 1 and 1.5 mm increments. The 
margin most frequently positive was the PV-SMVm, respec-
tively 22% for 0 mm margin, 50% and 50.7% for 1 and the 
1.5 mm increments (1 vs 1.5 NS). The SMAm and Pm were 
invaded respectively in 11.6% and 10% for 0 mm margin, 
34% and 36.2% for 1 mm increment, 37% and 38.4% for 
1.5 mm increment (NS). Factors associated with a signifi -
cantly increased risk of a positive margin were tumor size 
(TS), T stage (T), Lymph Node Ratio and VR in the univari-
ate analysis, but only T for 1 mm increment (p < 0.0476; OR: 
5.51) and TS for 1.5 mm increment (p < 0.0422; OR: 3.23) 
in the multivariate analysis.
Conclusion: Almost 70% of the patients had at least one 
positive margin with the systematic use of a SPHE. 
PV-SMVm was the most frequently positive margin. Those 
results may be a plea for future clinical trials of neoadjuvant 
treatment and a potentially signifi cant step toward stratifi ca-
tion of patients for further adjuvant treatments after resec-
tion. Data checks are still ongoing and the planned next step 
is to study the impact of the margin status on the survival of 
our patients (with each increment).
PL15
EFFECT OF SUPRACOLIC VERSUS 
INFRACOLIC GASTROJEJUNOSTOMY 
ON GASTRIC EMPTYING IN PATIENTS 
UNDERGOING WHIPPLES 
PANCREATICODUODENECTOMY – 
A PROSPECTIVE RANDOMIZED 
CONTROL TRIAL
P. Rebala1, V. Rao Guduru1, S. Patil1, K. Kumaresan2, 
U. Rao Balmoori1, R. Dama1, J. Magnus1 and 
N. R. Duvvuru1
1Asian Institute of Gastroenterology, Hyderabad, India; 
2KK Nuclear Scan, Hyderabad, India
Introduction: Major cause of morbidity following pancrea-
ticoduodenectomy is delayed gastric emptying. The reported 
incidence varied from 14% to 61%. Various technical and 
therapeutic measures have been advocated to minimise the 
problem. One of the technical factors was construction of 
gastrojejunostomy (antecolic vs retrocolic). The present ran-
domised study compares the infl uence of two techniques of 
gastrojejunostomy on gastric emptying both subjectively and 
objectively.
Methods: Patients undergoing whipples pancreaticoduo-
denectomy since Jan 2009 were randomised to either infra-
colic (Group A) or supracolic gastrojejunostomy (Group B). 
Patients in Group A, the stomach was mobilised and an 
infracolic gastrojejunostomy (GJ) was done. In Group B, the 
anastomosis was done in the supracolic area. Nasogastric 
tube was removed by 3rd postoperative day, if the aspiration 
is less than 200 ml/day. Patients with delayed gastric 
emptying (DGE), mechanical causes were ruled out. DGE 
was defi ned using ISGPS criteria. All eligible patients under-
went liquid and solid radioisotope gastric emptying after 
postoperative day 7. Clinical DGE, objective radio isotope 
liquid and solid emptying were compared between both 
groups.
Results: Out of 91 patients, 41 were randomised to infra-
colic GJ and 42 to supracolic GJ. In the infracolic group one 
patient died and in supracolic three patients died. Forty eight 
patients in the infracolic and 39 in the supracolic group were 
evaluated. Various demographic and disease factors were 
comparable between the groups. Clinical evidence of DGE 
(grade B and C) was signifi cantly high in the supracolic 
group (18/39) vs Infracolic group (5/48). Radioisotope liquid 
emptying was signifi cantly delayed in supracolic group 
(30/39) vs Infracolic group (22/48). No signifi cant difference 
in radioisotope solid emptying. Early nasogastric tube 
removal, liquid and solid diet tolerance was better in patients 
undergoing infracolic GJ.
Conclusion: During whipples pancreaticoduodenectomy, 
infracolic GJ is associated with signifi cantly low incidence 
of DGE. Radioisotope liquid emptying is better in infracolic 
GJ. Radioisotope solid emptying though better in infracolic 
GJ, did not reach statistical signifi cance. Patients with infra-
colic GJ had early removal of nasogastric tube and were able 
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to tolerate liquid and solid diet early than patients with supra-
colic GJ.
PL16
COMPUTED TOMOGRAPHY 
ENHANCEMENT AND PATIENT 
CHARACTERISTICS AS PREDICTORS 
OF COMPLICATIONS AFTER 
PANCREATICODUODENECTOMY
J. McAuliffe, K. Parks, S. McNeal, D. Morgan and 
J. Christein
University of Alabama at Birmingham, Birmingham, AL, 
USA
Introduction: Obesity correlates with morbidity after gas-
trointestinal operations and more specifi cally pancreaticodu-
odenectomy (PD). A Hounsfi eld Unit (HU), applied to 
computed tomography (CT), measures tissue density. The 
purpose is to determine whether lower HU score, which 
refers to less dense tissue and a higher degree of steatosis, 
predicts complications.
Methods: Patients undergoing PD from 2005–2010 were 
analyzed according to NSQIP risk, the Clavien complication, 
and the International Study Group on Pancreatic Fistula (PF) 
classifi cation systems. Noncontrast Computed Tomography 
(CT) Hounsefi eld units (HU) of viscera from a representative 
sample of patients were measured by a blinded assessor. 
Univariate and multivariate analyses were performed.
Results: Three hundred thirty-three patients underwent PD 
for malignant (57%) and benign disease. Mean blood loss 
(EBL) was 340 mL, 19% underwent a transfusion, and 
median stay was 8 days. Overall complication and PF rate 
was 66% and 20%, respectively. Patients with BMI > 25 had 
a higher rate of PF (32%, p < 0.01) as well as any complica-
tion (73%, p < 0.01). Patients were more likely to develop 
any complication as HU decrease for pancreas (p = 0.04), 
muscle (p < 0.01), spleen (p < 0.01), and liver (p < 0.01). 
Multivariate analysis of CT measurements for muscle 
(p = 0.02), liver (p = 0.04), and spleen (p < 0.05) remained 
independent predictors of complications when adjusting for 
BMI, age, gender, EBL, and transfusion.
Conclusion: Post-operative complications remain prevalent 
and imaging characteristics are independent predictors of 
morbidity after PD. A higher degree of steatosis of tissues 
correlates with complications and surgeons should consider 
CT characteristics as adjunctive predictors along with patient 
factors when discussing morbidity with patients regarding 
PD.
PL17
SHORT AND LONG TERM OUTCOMES 
AFTER THE FREY PROCEDURE
H. Ramesh, S. Rather, M. Wani, S. Mahesh, 
B. Venugopal, A. Venugopal, D. Vaishnav and 
S. Padman
Lakeshore Hospital, Cochin, Kerala, India
Introduction: Data regarding long term outcomes after 
surgery for chronic pancreatitis are lacking.
Methods: The aim of this study is to determine the long 
term outcomes after Frey Procedure for chronic pancreatitis 
over a period 1993 to 2010. 541 patients (333 males, 208 
females, age range 6 to 75 years, median 43 years) underwent 
Frey procedure. Outcomes studied were mortality, morbidity, 
pain relief, changes in exocrine/endocrine status and quality 
of life. Factors affecting outcome were studied by univariate 
and multivariate analysis. Minimum follow up was 1 year 
and maximum 18 years (median 112 months).
Results: 5 patients died, all in the period 1993–2000 (pan-
creatic leak with secondary hemorrhage (n = 2), intra abdom-
inal sepsis secondary to leak (n = 1), ARDS (n = 1) and 
unexplained (n = 1). Postoperative complications occurred 
in 23% of patients (intra abdominal collection, postoperative 
chest infection, fever, pancreatic leak, delayed gastric empty-
ing, bleed, wound infection). 15 patients died due to intercur-
rent and related illnesses during follow up. Pain relief 
occurred in 454 patients (84%) at the end of 1 year. In the 
period 1–5 years, 55 patients underwent reintervention/reop-
eration. The pain relief fi gure at 5 years was 94%. Endocrine 
status improved in 18% and worsended in 16%. Residual 
calculi correlated with poor outcome. 92% had good QOL.
Conclusion: Surgery relieves pain and provides good 
quality of life in over 90% of patients with chronic pancrea-
titis in the long term. Pancreatic function is maintained over 
this period.
PL18
CHANGE OF NUTRITIONAL INDEX, 
PANCREAS FUNCTION AND QUALITY 
OF LIFE AFTER PANCREATECTOMY: 
PROSPECTIVE STUDY
J. W. Park, J.-Y. Jang, M. J. Kang, I. W. Han, S.-W. Kim 
and E.-J. Kim
Departments of Surgery, Seoul National University College 
of Medicine, Seoul, Korea
Introduction: Pancreatectomy is major treatment modality 
for various pancreas and periampullary diseases. But still 
there are a few studies concerning with change of nutritional 
index, pancreas function and quality of life after pancreate-
ctomy with regular interval follow up.
Methods: From 2007 to 2011, we analysed 142 consecutive 
pancreatectomy patients. Relative body weight (RBW), 
Triceps skinfold thickness (TSFT), Serum protein/albumin, 
transferrin, fasting blood sugar (FBS), Oral glucose tolerance 
test (oGTT), HbA1c, EORTC QLQ-C30 questionnaire were 
collected serially (preoperative, postoperative, 3-month, 
6-month, 12-month).
Results: RBW (107.7, 102.0, 101.0, 102.8, 103.6; respec-
tively preoperative, postoperative, 3-month, 6-month, 
12-month) TSFT (13.3, 13.0, 12.0, 12.5, 12.3) recover at 
6-month, whereas transferrin, albumin, protein recover at 3 
month. DM or impaired fasting glucose (IFG)/impaired 
glucose tolerance (IGT) recover slowly to 12-month (34.8, 
69.4, 63.7, 50.8, 53.9; % of total numbers). Also steatorrhea 
decrease slowly (31.5, 37.5, 35.2, 31.9, 27.8%). Global 
health status/QoL and functional scales recover to preopera-
tive score at 3 month and improve to higher than preoperative 
score (61.7, 41.2, 63.4, 67.4, 71.3). Multivariate analysis 
reveals extensive operation, adjuvant therapy have signifi -
cant impact on nutritional index, pancreas function and 
quality of life.
Conclusion: Nutritional index, pancreas function and 
quality of life recover at 3-month and 6-month after pancrea-
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tectomy. Patients with extensive operation, adjuvant therapy 
need more careful follow-up and supportive management.
PL19
EFFICACY AND COST-BENEFIT 
ANALYSIS OF MESH REINFORCEMENT 
OF STAPLED LEFT PANCREATECTOMY: 
RESULTS OF A RANDOMIZED 
CONTROLLED TRIAL
K. Idrees1, J. Edler2, D. Lambert2, D. Linehan1, R. Fields1, 
S. Strasberg1, S. Kymes2 and W. Hawkins1
1Hepatobiliary, Pancreatic and Gastrointestinal Surgery, 
Department of Surgery, Washington University, St. Louis, 
MO, USA; 2Center for Economic Evaluation in Medicine, 
Washington University, St. Louis, MO, USA
Introduction: Pancreatic leak is a morbid complication fol-
lowing left pancreatectomy resulting in prolonged hospitali-
zations, additional diagnostic testing and invasive procedures. 
We hypothesized that mesh reinforcement of stapled left 
pancreatectomy would result in decreased pancreatic leak 
rate and cost benefi ts for the health care system.
Methods: A randomized, single-blinded, parallel-group trial 
of mesh versus no mesh reinforcement of left pancreatec-
tomy was performed. Clinically signifi cant leak, length of 
stay and cost benefi t were compared. A cost-benefi t model 
was developed to estimate net cost savings from payor’s 
perspective based on 2010 Medicare allowable charges and 
our institutional fi xed mesh cost of $165/procedure. A 
two-way sensitivity analysis was conducted to determine the 
model’s sensitivity to fl uctuations in cost of mesh and the 
effectiveness of mesh in reducing clinically signifi cant leaks.
Results: One-hundred patients were randomized. Pancreatic 
leaks (ISGPF grade B & C) were seen in 24% (11/46 patients) 
with no mesh compared to 1.9% (1/54 patients) with mesh 
reinforcement (p = 0.0007). The no-mesh group had longer 
median days with a drain (17 vs. 9, p = 0.0009) and an 
increased number of drain replacements (11 patients vs. 1 
patient, p = 0.001) compared to the mesh group. Average 
total costs for an episode of care were $7,410 and $7,760 for 
subjects receiving mesh or no-mesh respectively, resulting 
in savings of $350. With a 1.9% probability of developing 
a clinically signifi cant leak using mesh reinforcement, the 
strategy remains cost-saving if mesh is priced < $515 based 
on two-way sensitivity analysis.
Conclusion: Mesh reinforcement decreases clinically sig-
nifi cant pancreatic leaks. Despite the additional cost of mesh 
reinforcement, a strategy of using mesh reinforcement results 
in overall cost savings for the health care system due to 
decreased rates of clinically signifi cant leaks. Mesh rein-
forcement of stapled left pancreatectomy should be incorpo-
rated into routine practice.
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ADULT PYOGENIC LIVER ABSCESS – 
A SERIES OF 731 CASES AND RISK 
FACTORS ASSOCIATED WITH FAILURE 
OF PERCUTANEOUS THERAPY
Z. J. Lo, J. J. Leow, H. Y. Lo, T. H. Loong, B. Wang, 
J. K. Low and W. W. Woon
Department of Surgery, Tan Tock Seng Hospital, Singapore
Introduction: Adult pyogenic liver abscess (PLA) is a 
major hepato-biliary infection with reported mortality rates 
of 5% to 25%. We aim to describe the characteristics, man-
agement and outcomes of PLA in Singapore, hence identify-
ing the risk factors associated with failure of initial 
percutaneous therapy.
Methods: A retrospective study of 731 PLA patients pre-
senting between 2001 and 2009 to Tan Tock Seng Hospital 
(Singapore), a tertiary hospital of 1400 beds was performed. 
Ameobic and hydatid abscesses were excluded. Demo-
graphic, clinical, biochemical, radiological and microbio-
logical data were analysed while management and outcomes 
were described. Univariate and multivariate analysis of 
comorbidities, biochemical markers, radiological features 
and management strategies were performed to identify risk 
factors associated with failure of percutaneous therapy.
Results: Of 731 patients (66% male) with median age of 62 
years old, 36% had type 2 diabetes mellitus. Mean abscess size 
was 6.4 cm. Blood cultures were positive in 34.8% of patients 
with 72.5% growing K. Pneumoniae. Mean intravenous anti-
biotic therapy duration was 11.4 days while mean oral antibi-
otic therapy was 30.8 days. 85% of patients underwent 
percutaneous drainage with mean drain duration of 7.6 days. 
Drain cultures were positive in 26.1% with 76.5% growing K. 
Pneumoniae. In the study, 3% required more than one drain-
age, 1% required open surgery, 12.2% were re-admitted and 
mortality rate was 12.2%. Old age (p = 0.004) and raised 
serum white cell count (p = 0.025) were found to be the only 
factors related to failure of initial percutaneous therapy.
Conclusion: The causative organism of PLA in Singapore 
is mostly Klebsiella Pneumoniae and fi rst-line management 
remains intravenous antibiotics and radiological drainage. 
However, a small proportion of patients, especially elderly 
patients who present with elevated serum white cell count, 
may still require surgical drainage.
PL21
LAPAROSCOPIC MAJOR LIVER 
RESECTION IN KOREA: 
A MULTICENTER STUDY
D. W. Hwang, H.-S. Han, Y.-S. Yoon, J. Y. Cho, J. H. Kim 
and Y. J. Kwon
Department of Surgery, Seoul National University Bundang 
Hospital, Seoul National University College of Medicine, 
South Korea
Introduction: The aims of this study are to present the 
experience of laparoscopic major liver resection in Korea 
based on multicenter retrospective study, to investigate the 
current status of laparoscopic liver resection (LLR) in Korea.
Methods: A total 1,009 LLRs between 2001 and 2011 were 
conducted in this study, and the data of these patients was 
retrospectively collected. Twelve tertiary medical centers 
with specialized hepatic surgeons participated in this study. 
Study group was identifi ed that the patients had benign and 
malignant hepatic disease including primary and metastatic 
hepatic tumors. Major/minor LLRs were performed in 
265/744 patients. LLRs were applied in the order of hepato-
cellular carcinoma, metastatic tumor, intrahepatic duct stone, 
etc. All of major LLRs were anatomical resections. Left 
hemihepatectomy was most frequent, and next was right 
hemihepatectomy.
Results: Pure/hand-assisted/laparoscopy-assisted laparo-
scopic liver resections were performed in 190/3/55 patient. 
Open conversion was performed in 17 cases (0.06%). Mean 
operative time and estimated blood loss in laparoscopic 
major liver resection was 399.3 ± 169.8 minutes and 836.0 
± 1223.7 ml. Intraoperative transfusion was required in 65 
patients (24.5%). Mean postoperative length of stay was 12.3 
± 7.9 days. Postoperative complication was detected in 53 
patients (20%), and in-hospital mortality in 2 patients 
(0.75%). Mean number and mean maximal size of resected 
tumor was 1.22 ± 1.54 and 40.0 ± 27.8 mm. R0 resection 
was obtained in 120 patients who had hepatic tumor, but R1 
in 8 patients. Mean distance of safe resection margin was 
14.6 ± 15.8 mm.
Conclusion: Several obstacles still remains related to longer 
operative time, larger amount of blood loss, higher rate of 
transfusion requirement and longer length of stay, although 
these were expectable when considering the extent of opera-
tion and these would be resolved in the near future. However, 
the present study identifi ed that laparoscopic major liver 
resection reached a certain standard in experienced group.
PL22
2012 LIVER RESECTIONS IN THE NEW 
MILLENNIUM: WE ARE FAR FROM 
ZERO MORTALITY
F. S. Ftériche, S. Dokmak, B. Aussilhou, O. Farges, 
A. Sauvanet and J. Belghiti
Department of Hepatobiliary and Pancreatic Surgery, 
Hospital Beaujon, Clichy, France
Introduction: Evaluate with a large unicentric series the 
surgical risk of elective liver resection in the new 
millennium.
Methods: From 2000, 2012 elective liver resections were 
prospectively analysed from a maintained database evaluat-
ing the surgical risk with 90 days mortality according to (a) 
patients risk (age > 60 years and ASA score); (b) nature of 
the disease: benign (n = 561; 27.8%) or malignant (n = 1451], 
including metastasis (n = 751), HCC (n = 450) and biliary 
cancer (n = 194)] (c) underlying liver parenchyma, classifi ed 
as normal (n = 480; 33%), diseased (steatosis > 30%, fi brosis, 
chemotherapy related toxicity, steatohepatitis, cholestasis) or 
cirrhosis (n = 363; 18%) and (d) the extent of the liver resec-
tion: minor (n = 928; 46%) or major (≥3 segments), subclas-
sifi ed without or with (n = 367; 18.2%) biliary, vascular or 
gastrointestinal associated procedure.
12 Plenary Session Abstracts
© 2012 The Authors
HPB © 2012 Americas Hepato-Pancreato-Biliary Association HPB 2012, 14 (Suppl. 2), 1–12
Results: Overall mortality and major morbidity rate was 
3.5% and 24.4%, respectively. Mortality for benign lesion 
was 0.7% vs 4.5% (p < 0.001) for malignant tumors rang-
ing from 8.2% for biliary tumors to 1.7% for metastasis. 
In malignant subgroup, multivariate analysis showed that 
the mortality was signifi cantly infl uenced by age > 60 years 
(p < 0.024); ASA score ≥3 (p < 0.015); presence of diseased 
parenchyma (p < 0.001); cirrhosis (p < 0.001); major resec-
tion (p = 0.011) and associated procedure ( < 0.001) espe-
cially when associated with vascular resection (p < 0.001).
Conclusion: This persistent important high mortality rate 
after elective liver resection for malignant disease is explained 
by resections performed in high risk patients with diseased 
liver requiring complex major procedure. A signifi cant 
decrease of operative risk in this population requires a reap-
praisal of major procedure in diseased liver.
PL23
VASCULAR INFLOW CONTROL DURING 
HEPATIC LOBECTOMY: A COMPARISON 
OF INTRAHEPATIC PEDICLE LIGATION 
AND EXTRAHEPATIC LIGATION
F. E. D’Amico1, P. Allen1, A. Eaton2, T. P. Kingham1, 
R. DeMatteo1, Y. Fong1, W. Jarnagin1 and M. D’Angelica1
1Department of Surgery, Memorial Sloan Kettering Cancer 
Center, New York, USA; 2Department of Epidemiology and 
Biostatistics, Memorial Sloan Kettering Cancer Center, 
New York, USA
Introduction: Intrahepatic pedicle ligation (PL) for vascu-
lar infl ow control during hepatic lobectomy is an alternative 
to extrahepatic portal dissection (ED). Although well-
described, concern has been raised over the possibility of 
increased complication rates with PL.
Methods: Patients who had undergone hepatic lobectomy 
between January 1995 and December 2010 were reviewed 
and the technique (PL vs ED) used for infl ow control docu-
mented. Patients who required a bile duct resection and 
patients who underwent trisegmentectomy were excluded. 
Patient and tumor related variables were reviewed to iden-
tify factors associated with the type of infl ow ligation. 
Treatment related variables and complication rates were 
also compared. Over the study period, 798 patients under-
went hepatic lobectomy by 6 different surgeons. There were 
568 (71%) right hepatectomies and 230 (28%) left hepatec-
tomies. PL was performed in 480 patients (60%), and ED in 
318 (40%). P value was considered statistically signifi cant 
under 0.05.
Results: In univariate analysis, factors signifi cantly associ-
ated with the use of PL were: surgeon, size of tumor < 5 cm, 
less then 3 tumors, right hepatectomy, portal vein emboliza-
tion, diagnosis of colon cancer metastasis. In multivariate 
analysis the use of PL was statistically associated with right 
hepatectomy (HR3.878) and a smaller size of the largest 
tumor (PL4.5 vs ED5.5 cm).The PL group had a signifi cantly 
longer Pringle time (PL40 vs ED20 min).There was no sig-
nifi cant difference in median operative time blood loss, post-
operative biloma (PL5.7% vs ED 5.1%), margin positivity 
(PL8.8% vs ED7.5%) between groups. Total complications 
were similar (PL49.8% vs ED 48.4%) as well as minor (PL 
27.5% vs 30.8%) and major (PL19.6% vs ED16%).90-day 
mortality was similar (PL2.7% vs ED1.6%).
Conclusion: Patients with small tumors undergoing a right 
hepatectomy were more likely to undergo PL. In selected 
patients, PL was not associated with an increased complica-
tion rate and should be considered a safe approach.
